Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer research hub

A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, vs Investigator's Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study is looking at a new medicine called farletuzumab ecteribulin for women with ovarian, primary peritoneal, or fallopian tube cancer that hasn't responded to previous platinum-based chemotherapy. Researchers want to see if this new drug shrinks tumours or stops them growing compared to standard treatments.